176 related articles for article (PubMed ID: 33362463)
1. AChR β-Subunit mRNAs Are Stabilized by HuR in a Mouse Model of Congenital Myasthenic Syndrome With Acetylcholinesterase Deficiency.
Karmouch J; Delers P; Semprez F; Soyed N; Areias J; Bélanger G; Ravel-Chapuis A; Dobbertin A; Jasmin BJ; Legay C
Front Mol Neurosci; 2020; 13():568171. PubMed ID: 33362463
[TBL] [Abstract][Full Text] [Related]
2. Neuromuscular junction immaturity and muscle atrophy are hallmarks of the ColQ-deficient mouse, a model of congenital myasthenic syndrome with acetylcholinesterase deficiency.
Sigoillot SM; Bourgeois F; Karmouch J; Molgó J; Dobbertin A; Chevalier C; Houlgatte R; Léger J; Legay C
FASEB J; 2016 Jun; 30(6):2382-99. PubMed ID: 26993635
[TBL] [Abstract][Full Text] [Related]
3. HuR Mediates Changes in the Stability of AChR β-Subunit mRNAs after Skeletal Muscle Denervation.
Joassard OR; Bélanger G; Karmouch J; Lunde JA; Shukla AH; Chopard A; Legay C; Jasmin BJ
J Neurosci; 2015 Aug; 35(31):10949-62. PubMed ID: 26245959
[TBL] [Abstract][Full Text] [Related]
4. Effect of Inhibiting p38 on HuR Involving in β-AChR Post-transcriptional Mechanisms in Denervated Skeletal Muscle.
Wang H; Zhao X; Yun W; Chen LH; Li ST
Cell Mol Neurobiol; 2019 Oct; 39(7):1029-1037. PubMed ID: 31172341
[TBL] [Abstract][Full Text] [Related]
5. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.
Ohno K; Ito M; Kawakami Y; Krejci E; Engel AG
Chem Biol Interact; 2013 Mar; 203(1):335-40. PubMed ID: 22981737
[TBL] [Abstract][Full Text] [Related]
6. ColQ controls postsynaptic differentiation at the neuromuscular junction.
Sigoillot SM; Bourgeois F; Lambergeon M; Strochlic L; Legay C
J Neurosci; 2010 Jan; 30(1):13-23. PubMed ID: 20053883
[TBL] [Abstract][Full Text] [Related]
7. [Congenital myasthenic syndromes].
Ohno K
Rinsho Shinkeigaku; 2012; 52(11):1159-61. PubMed ID: 23196549
[TBL] [Abstract][Full Text] [Related]
8. [Congenital myasthenic syndromes: phenotypic expression and pathophysiological characterisation].
Andreux F; Hantaï D; Eymard B
Rev Neurol (Paris); 2004 Feb; 160(2):163-76. PubMed ID: 15034473
[TBL] [Abstract][Full Text] [Related]
9. Molecular Analysis of a Congenital Myasthenic Syndrome Due to a Pathogenic Variant Affecting the C-Terminus of ColQ.
Barbeau S; Semprez F; Dobbertin A; Merriadec L; Roussange F; Eymard B; Sternberg D; Fournier E; Karasoy H; Martinat C; Legay C
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003406
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterases regulation in the absence of ColQ.
Sigoillot SM; Bourgeois F; Legay C
Chem Biol Interact; 2010 Sep; 187(1-3):84-9. PubMed ID: 20153305
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes.
Mihaylova V; Müller JS; Vilchez JJ; Salih MA; Kabiraj MM; D'Amico A; Bertini E; Wölfle J; Schreiner F; Kurlemann G; Rasic VM; Siskova D; Colomer J; Herczegfalvi A; Fabriciova K; Weschke B; Scola R; Hoellen F; Schara U; Abicht A; Lochmüller H
Brain; 2008 Mar; 131(Pt 3):747-59. PubMed ID: 18180250
[TBL] [Abstract][Full Text] [Related]
12. Developmental consequences of the ColQ/MuSK interactions.
Karmouch J; Dobbertin A; Sigoillot S; Legay C
Chem Biol Interact; 2013 Mar; 203(1):287-91. PubMed ID: 23089045
[TBL] [Abstract][Full Text] [Related]
13. End-plate gamma- and epsilon-subunit mRNA levels in AChR deficiency syndrome due to epsilon-subunit null mutations.
Croxen R; Young C; Slater C; Haslam S; Brydson M; Vincent A; Beeson D
Brain; 2001 Jul; 124(Pt 7):1362-72. PubMed ID: 11408331
[TBL] [Abstract][Full Text] [Related]
14. Acetylcholinesterase and molecular interactions at the neuromuscular junction.
Guerra M; Cartaud A; Cartaud J; Legay C
Chem Biol Interact; 2005 Dec; 157-158():57-61. PubMed ID: 16289501
[TBL] [Abstract][Full Text] [Related]
15. [Molecular bases and therapeutic strategies in defective neuromuscular transmissions: lessons learned from a prototypical synapse].
Ohno K; Ito M; Masuda A
Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Aug; 29(4):145-51. PubMed ID: 19764481
[TBL] [Abstract][Full Text] [Related]
16. Congenital myasthenic syndromes with acetylcholinesterase deficiency, the pathophysiological mechanisms.
Legay C
Ann N Y Acad Sci; 2018 Feb; 1413(1):104-110. PubMed ID: 29405353
[TBL] [Abstract][Full Text] [Related]
17. Roles of collagen Q in MuSK antibody-positive myasthenia gravis.
Ohno K; Otsuka K; Ito M
Chem Biol Interact; 2016 Nov; 259(Pt B):266-270. PubMed ID: 27119269
[TBL] [Abstract][Full Text] [Related]
18. Protein-anchoring therapy to target extracellular matrix proteins to their physiological destinations.
Ito M; Ohno K
Matrix Biol; 2018 Aug; 68-69():628-636. PubMed ID: 29475025
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular analysis of a novel COLQ missense mutation causing congenital myasthenic syndrome in a Syrian family.
Matlik HN; Milhem RM; Saadeldin IY; Al-Jaibeji HS; Al-Gazali L; Ali BR
Pediatr Neurol; 2014 Jul; 51(1):165-9. PubMed ID: 24938146
[TBL] [Abstract][Full Text] [Related]
20. Splicing regulation and dysregulation of cholinergic genes expressed at the neuromuscular junction.
Ohno K; Rahman MA; Nazim M; Nasrin F; Lin Y; Takeda JI; Masuda A
J Neurochem; 2017 Aug; 142 Suppl 2():64-72. PubMed ID: 28072465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
